The Future in Cannabis. WorldWide.

Tag: ACMPR

MYM Nutraceuticals to develop the cannabis “gold standard” for product testing process and technology in Canada

Vancouver, British Columbia, Canada / TheNewswire / April 5, 2017MYM Nutraceuticals Inc. (CSE : MYM ) (OTC:MYMMS)(FRA:OMY), (the “Company” or “ MYM ”) is looking to lead the Canadian market by establishing the gold standard in quality assurance testing of its cannabis products. MYM has hired TheraCann Canada to implement its full suite of services including ISO 17025(2005) compliance to ensure repeatable and reliable data stands behind each product label. TheraCann Canada is also providing TheraCannSYSTEM software to MYM which directly captures all testing and analysis data to better control regulatory compliance concerns and future audits by Health Canada.

With the recent announcement that the Canadian Provinces to be able to decide how cannabis will be distributed within their borders, the federal government will oversee all medical and recreational marijuana cultivation. MYM is planning to jump ahead of the curve on future legislation to focus on in-house quality assurance testing laboratories and analytics.

Brent McNiven, President of, TheraCann Canada commented:   With the recent flurry of dangerous recalls in the Canadian market due, in part, to a lack of tighter government control on standards, we expect Health Canada will finally be moving to a stronger and more regulated testing procedure in advance of recreational legalization. TheraCann’s “gold standard” process build on ISO 17025 (2005) will meet or exceed all future regulations and ensure MYM is ready to excel in this rapidly expanding market.

Jonathan Fiteni, MYM CEO, commented :   MYM is looking to build the industry standard in all-inclusive cannabis facilities to meet the demands of the Canadian consumer. With the anticipated start of recreational legalization coming online in the summer of 2018, MYM will be positioned to provide the safest products in the market.

ABOUT MYM

MYM Nutraceuticals Inc. (CSE:MYM)(OTC:MYMMS)(FRA:OMY) is a public company trading on the Canadian Stock Exchange whose primary focus is developing high-end organic medicinal marijuana supplements and topical products. MYM also has an interest in the development of high-density farming facilities and technologies that allow MYM to expand its brand into the global market.

ABOUT THERACANN CANADA

TheraCann Canada Benchmark Corporation offers a one-stop, full-service solution for the Canadian cannabis marketplace. From regulatory applications, planning, facility design, cultivation, marketing and communications, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements. TheraCann Canada is subsidiary of TheraCann International Benchmark Corporation. More information about TheraCann is available at www.theracanncorp.com.

 

Health Canada Marijuana Testing: Transparency or Hypocrisy?

Testing procedures

A report published by the Globe and Mail this week once again called into question the ethical and practical standards to which Health Canada operates their medical cannabis testing programs. During a random screening by Health Canada, the Toronto based Licensed Producer, Mettrum Ltd. was found to be using the pesticides Myclobutanil and Pyrethrin. Myclobutanil is deemed so dangerous that Washington, Colorado and Oregon all moved very quickly to ban its use in cannabis grow operations due to potentially fatal hydrogen cyanide emissions when heated. Though Mettrum issued a recall on November 1st, the public and consumers were never informed of the findings by the company or Health Canada.

This is not the first time that Health Canada has withheld information from the public on the use of dangerous chemicals in tested cannabis. In September of this year a Globe investigation revealed that nearly 60% of samples tested in unlicensed Vancouver dispensaries in 2015 also contained pesticides, fecal bacteria, yeast and mold, and were not safe for human consumption. Despite the legal vacuum in which these dispensaries operate, it was nevertheless surprising that Health Canada did not act to protect Canadian citizens from harm. Now that they have once again failed to act in the best interests of the people they are sworn to protect, hard questions need to be asked of the decision makers who are putting large swaths of our populous at risk of disease or death.

There are hundreds of ACMPR applicants currently held up in the licensing process with Health Canada. Many of these newer applicants recognize the need for the highest quality ISO 17025 testing standards for cannabis, but are languishing – some for years – in the Health Canada queue. The government appears to be protecting existing LP’s from the legal consequences of using illegal and dangerous substances in their cultivation practices, while simultaneously excluding higher quality competition.  At best this is a double standard, and at worst it brings the entire ACMPR mechanism into disrepute and smells of willful blindness. This is a critical period of rapid expansion for this industry and as companies work towards legitimacy they should not be let down by the very mechanism which governs them.

It is time to reexamine the process from within. Health Canada and the LP’s it regulates must begin to operate in a transparent manner, with the safety of the Canadian public being the highest priority. This requires not only full public disclosure when cannabis containing hazardous substances are released to the public, but testing programs that identify these substances before they are released. The following protocols and principals should be adopted by all LP’s and strictly enforced by Health Canada:

  • ISO17025(2005) laboratory data must be the standard to which all testing laboratories are held.
  • At the present time, LP’s are permitted to submit samples to a variety of unaccredited 3rd party Mom and Pop labs, and cherry pick the results that are most favorable. This practice is dangerous and must stop.
  • Health Canada must act in the best interests of the Canadian public, and not be seen as acting in concert with the largest producers to conceal the presence of toxic substances in the cannabis they sell.
  • Whenever Health Canada finds instances of contaminated cannabis being released to the Canadian public, be it through an LP or otherwise, this information must be disclosed immediately and not years later through a freedom of information act order.

Health Canada Meets Federal Court Deadline!

HC-signature v2On August 11 Health Canada (HC) announced that they will meet the court imposed August 24 2016 deadline for revising the Marihuana for Medical Purposes Regulations (MMPR) . The regulations are now called the Access to Cannabis for Medical Purposes Regulations (ACMPR). These new regulations will replace the MMPR as of August 24, 2016, and are being implemented as a result of the Federal Court ruling in the case of Allard v. Canada. Health Canada has issued a fact sheet – http://news.gc.ca/web/article-en.do?nid=1110409 – with the complete set of regulations to be published on the HC website August 24, 2016.

Read more

TheraCann completes Zenalytic Laboratories!

Zen_Labs_logoTheraCann International Corporation (formerly Benchmark Labs) is happy to announce that it has has completed the plan, design, implementation, and training of the core staff  of Zenalytic Laboratories (Zen Labs) that includes the installation, training and support of the TheraCann BenchmarkSYSTEM secure Web based software.

Zen Labs is currently conducting water and soil ISO 17025(2005) analysis while it waits for Health Canada approval for it to also then possess, analyze, transport and destroy medical marijuana.

Read more